Vice President, Islet Cell Therapy Research

  Sigilon Therapeutics is a multidisciplinary biotechnology company which specializes in creating immune privileged products to address unmet clinical needs. Sigilon Therapeutics’s technology has the ability to completely transform how we treat patients with chronic diseases. Originated from Robert Langer and Daniel Anderson’s laboratories of MIT and was patented and published in three seminal reports in Nature Materials, Nature Biotechnology, and Nature Medicine in 2015 and 2016. The company is based in Cambridge, MA and is funded by Flagship Pioneering. Now is the time to get in on the ground floor of a fast growing company with a very interactive and open culture. Please forward your application via email to

Sigilon Therapeutics is searching for an energized candidate to lead a new team of diabetes focused scientists to develop a novel therapeutic product for diabetes utilizing Sigilon’s Afibromer™ technology combined with leading edge islet cell technology.  This group would have primary responsibility for research and early development of an encapsulated allogeneic islet cell product. Initial emphasis will be on developing a robust, reproducible and scalable b-cell differentiation protocol as well as overseeing relevant pre-clinical experiments and development activities to include IND enabling studies; tech transfer to a CMO; etc. The team will have full access to all of Sigilon’s cell biology and encapsulation chemistry expertise along with substantial designated funds to enable a rapid pursuit of a very robust and competitive program.